Company intelligence / Profile preview
Azurity Pharmaceuticals
Woburn, Massachusetts, United Statesazurity.com ↗
- Ownership
- Private
- Employees
- ~582
- Development stage
- Commercial
01
Overview
Azurity specializes in providing innovative dosage forms for overlooked patients. They recently completed the acquisition of Covis Pharma in March 2025, expanding their global footprint to over 50 countries. They also received FDA approval for Danziten (nilotinib tablets), the first nilotinib with no mealtime restrictions for treating Philadelphia chromosome positive chronic myeloid leukemia.
- Therapeutic areas
- GastroenterologyPulmonologyCardiovascularEndocrinologyImmunologyHematologyOncologyNeurologyInfectious Diseases
- Modalities
- Small moleculesinnovative dosage forms
- Industry
- Biotech
02
Drug pipeline
24 assets23 more assets in the full pipeline.
Beyond the preview
Go deeper on Azurity Pharmaceuticals.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Azurity Pharmaceuticals.